XML 13 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 9 Months Ended 141 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Costs and expenses:          
Research and development $ 714 $ 156 $ 1,141 $ 901 $ 43,818
Selling, general and administrative 1,011 772 2,852 2,579 45,435
Merger transaction costs         5,470
Restructuring expense, net         2,413
Loss on impairment of in-process research and development         6,000
Total costs and expenses 1,725 928 3,993 3,480 103,136
Loss from operations (1,725) (928) (3,993) (3,480) (103,136)
Gain on assignment of patent rights         2,000
Gain on bargain purchase         25,282
Interest and other income 2 2 3 3 2,031
Interest and other expense   (1) (3) (3) (445)
Loss before income taxes (1,723) (927) (3,993) (3,480) (74,268)
Benefit from income taxes         2,281
Net loss and comprehensive loss (1,723) (927) (3,993) (3,480) (71,987)
Less: Accretion of redeemable convertible preferred stock         (245)
Less: Deemed preferred stock dividend     (2,026)   (2,807)
Net loss attributable to common stockholders $ (1,723) $ (927) $ (6,019) $ (3,480) $ (75,039)
Net loss attributable to common stockholders per share:          
Basic and diluted $ (0.16) $ (0.41) $ (0.96) $ (1.65)  
Weighted average shares outstanding:          
Basic and diluted 10,832,516 2,283,736 6,299,828 2,113,679